ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 63.99 Closing the day 09:45 at 63.27 -0.36 -0.57% With a day low of 63.22 and a total volume of 333,039.

ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/

ABBV Abbvie Inc. Common Stock Recent Headline News

Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 321.64 (+5.16), FB: 74.36 (+0.11), ABBV: 63.25 (-0.38), GOOGL: 553.63 (-2.81), GOOG: 543.15 (-2.23)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.69 (-0.38), GILD: 102.12 (-2.08), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)

If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST

GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38)

Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST

JNJ: 108.69 (-0.38), PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)

AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.25 (-0.38)

Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.87 (+0.38), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.51 (+0.30), JNJ: 108.69 (-0.38), GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)

Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.51 (+0.30), ABBV: 63.25 (-0.38), SNY: 46.33 (-0.20), REGN: 399.88 (-2.75)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), DNDN: 0.12 (-0.01), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75)

Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 141.97 (-0.74), ACT: 244.25 (+2.62), CBG: 32.45 (-0.24), HCP: 43.58 (-0.34), BCR: 164.69 (-0.90), PCG: 49.87 (+0.10), AMGN: 158.70 (-2.15), CB: 101.57 (+0.10), SRE: 109.21 (-0.30), PLD: 41.03 (-0.07), HSP: 57.46 (-0.63), TWX: 79.34 (+0.36), KIM: 24.63 (-0.11), CMI: 143.84 (-0.68), ALXN: 190.28 (-3.31), ESS: 200.29 (-0.23), ABBV: 63.25 (-0.38), CAT: 100.72 (-0.39), AAPL: 113.16 (+0.34)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.51 (+0.30), GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)

Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST

ABBV: 63.25 (-0.38)

Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST

SHPG: 201.15 (-1.27), PFE: 30.47 (+0.05), AZN: 72.95 (-1.58), ABBV: 63.25 (-0.38), WAG: 66.99 (+0.03)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.39 (-0.35), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33), ENTA: 43.20 (-0.02)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), MRK: 59.34 (-0.20), DNDN: 0.12 (-0.01), AZN: 72.94 (-1.59), TEVA: 57.14 (-0.03), ABBV: 63.25 (-0.38), GSK: 45.64 (-0.02), BMY: 57.49 (-0.31), NVS: 93.52 (-0.86)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.56 (+0.15), YHOO: 50.69 (+0.19), AMZN: 321.65 (+5.17), BIIB: 311.18 (-6.80), VRTX: 112.37 (-0.35), FEYE: 32.95 (-0.39), LNKD: 230.94 (+1.17), EBAY: 54.23 (-0.14), GILD: 102.13 (-2.07), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75), CELG: 105.74 (-1.69)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.46 (-0.28), ABBV: 63.25 (-0.38), BMY: 57.49 (-0.31), ENTA: 43.20 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 128

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 197

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 107

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 37

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 237

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading

Top 5 Most Recently Viewed Articles

Tarkett Updates on Voting Rights and Share Capital Structure

Updated Category News Views 57

Tarkett's Current Voting Rights and Share Capital The information regarding Tarkett’s share capital and the total number of voting rights reflects vital details for investors and stakeholders. As of the designated date, Tarkett boasts a significant total number of shares that contribute to its economic activities. Understanding Voting Rights in Tarkett As a significant...

Continue Reading
Quiddity Engineering Welcomes Ryan Quinn as New GM in Texas

Updated Category News Views 267

Quiddity Engineering Introduces Ryan Quinn, PE, as General Manager Quiddity Engineering is thrilled to share the news of Ryan Quinn, PE, joining the team as the General Manager for its Central Texas region. This appointment signifies a key strategic move for the organization, as Ryan brings over 18 years of invaluable experience in the consulting engineering landscape....

Continue Reading
Pure Roofing Unveils Innovative Office Space Focused on Growth

Updated Category News Views 206

Pure Roofing Launches New Office to Elevate Employee Culture Pure Roofing has recently expanded by opening a new office, reflecting a commitment to employee well-being and community engagement. Featuring a unique design that includes an indoor basketball court, this innovative space aims to enhance teamwork, productivity, and wellness among staff. The establishment of...

Continue Reading
Crown Point Energy Reports Q3 Financial Performance Highlights

Updated Category News Views 207

Crown Point Energy Announces Financial Results for Q3 Crown Point Energy Inc. recently shared its operating and financial results for the period ending September 30, 2024. These insights reflect the company’s performance amidst varied market conditions. Financial Overview of Q3 2024 In Q3 2024, Crown Point faced several challenges but also solid achievements: Reported a...

Continue Reading
Empowering Financial Innovation: Semifinalists of 2024 Edition

Updated Category News Views 125

Milken-Motsepe Prize in FinTech Announces Semifinalists The Milken Institute and the Motsepe Foundation have revealed the 10 standout teams that have advanced to the Semifinalist Round of the prestigious Milken-Motsepe Prize in FinTech, each securing $100,000 in funding to fuel their innovative projects. Driving Financial Inclusion Through Innovation This esteemed prize...

Continue Reading